Buying Rémy Martin? Start here. From VSOP to XO, its Fine Champagne core and lees distillation deliver a richer, smoother, ...

The Philippine National Police’s detention facility at Camp Crame will be demolished to give way to a new office building, ...

MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M 1 ...

Skip the unicorns. Kentucky’s best bourbon values are the bottles you can buy—under $40: outstanding quality, incredible ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

The Bank of England is expected to triple the spend involved with its cloud migration, from £7 million to £21.5 million, per ...

MapLight Therapeutics, Inc. ("MapLight") (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

STOLI announced the launch of STOLI Halapeño Pepper, a new flavored vodka crafted to elevate one of the world’s most iconic ...

“Dry January isn’t about going without, it’s about choosing better,” said Blair MacNeil, President, Tilray Canada. “From ...

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.

The Alpestria-1 study enrolled (in France, USA and Spain) 26 patients with Alport syndrome at high risk of a rapid loss of kidney function despite stable multiple SoC drugs, including ...

GSK reports positive results from B-Well 1 & B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B: London, UK Thursday, January ...